Unichem Laboratories Limited

UNICHEMLAB

INE351A01035

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:10:06 2024-05-02 am EDT			5-day change	1st Jan Change
585 ^INR	-0.58%		+1.31%	+43.77%

Mar. 29	Unichem Laboratories Limited Announces Board Resignations, Effective March 31, 2024	CI
Mar. 27	Unichem Laboratories Chief Commercial and International Business Development Officer Steps Down	MT

Unichem Laboratories Limited Announces Resignation of Santosh Mahil as Chief Commercial & International Business Development Officer

March 27, 2024 at 06:39 am EDT

Unichem Laboratories Limited announced resignation of Mr. Santosh Mahil as Chief Commercial & International Business Development officer. Date of cessation: 27th March 2024. Due to personal reasons.

Latest news about Unichem Laboratories Limited

Unichem Laboratories Limited Announces Board Resignations, Effective March 31, 2024	Mar. 29	CI
Unichem Laboratories Chief Commercial and International Business Development Officer Steps Down	Mar. 27	MT
Unichem Laboratories Limited Announces Resignation of Santosh Mahil as Chief Commercial & International Business Development Officer	Mar. 27	CI
Unichem Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 05	CI
Indian Equities Close Marginally Higher Ahead of IT Earnings	Jan. 11	MT
Unichem Laboratories Gets US FDA Approval for Generic Hypertension Drug	Jan. 11	MT
Unichem Laboratories Limited Receives Anda Approval for Its Doxazosin Tablets USP, 1 Mg, 2 Mg, 4 Mg and 8 Mg	Jan. 11	CI
Unichem Laboratories Completes Sale of Entire Stake in Optimus Drugs	Dec. 05	MT
Unichem Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 01	CI
Ipca Laboratories Limited completed the acquisition of 19.29% stake in Unichem Laboratories Limited for INR 6 billion.	23-09-07	CI
Unichem Laboratories Gets US FDA Nod for Prasugrel Tablets	23-08-29	MT
Unichem Laboratories Limited Receives ANDA Approval for its Prasugrel Tablets USP, 5 Mg and 10 Mg from the United States Food and Drug Administration	23-08-29	CI
Unichem Laboratories Limited Announces the Resignation of Dilip Kunkolienkar as Member of the Audit Committee and Risk Management Committee of the Board of Directors	23-08-09	CI
Ipca Laboratories Acquires 33% Stake in Unichem for INR9.45 Billion	23-08-02	MT
Unichem Laboratories Trims Consolidated Net Loss in Fiscal Q1	23-07-14	MT
Unichem Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-07-14	CI
Unichem Laboratories Swings to Loss in Fiscal Q4	23-05-24	MT
Unichem Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-23	CI
Transcript : Ipca Laboratories Limited, Unichem Laboratories Limited - M&A Call	23-04-25
Ipca Laboratories to Acquire 33% Stake in Unichem for INR10.3 Billion	23-04-25	MT
INDIA STOCKS-Indian shares flat ahead of key earnings; IT, pharma stocks slide	23-04-25	RE
INDIA STOCKS-Indian shares flat ahead of key earnings; IT, pharma stocks fall	23-04-25	RE
India's Ipca Laboratories sinks to 3-yr low after Unichem Lab deal	23-04-25	RE
Indian pharma Ipca Labs to buy over 33% stake in Unichem	23-04-24	RE
Ipca Laboratories Limited made an offer to acquire a 26% stake in Unichem Laboratories Limited for INR 8 billion	23-04-23	CI

Chart Unichem Laboratories Limited

Duration

Period

More charts

Unichem Laboratories Limited is an India-based international, integrated, specialty pharmaceutical company. The Company is focused on product development, process chemistry and manufacturing complex active pharmaceutical ingredients (API) as well as dosage forms. It manufactures and markets pharmaceutical formulations as branded generics as well as generics in several markets across the world. It has several pharma products that address the needs of various therapeutic areas, such as gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterial, anti-infectives and pain management. The Company is also engaged in contract manufacturing with the focus on immediate-release dosage forms, extended-release dosage forms: matrix and pellets, dry powder injections and syrups, novel drug delivery systems, and technology transfer and documentation. Its subsidiaries include Unichem Pharmaceuticals (USA) Inc, Unichem Farmaceutica Do Brasil Lta and Niche Generics Limited UK.

Sector

Pharmaceuticals

Calendar

2024-05-23 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
UNICHEM LABORATORIES LIMITED	+43.77%	496M
ELI LILLY AND COMPANY	+29.68%	699B
NOVO NORDISK A/S	+25.07%	571B
JOHNSON & JOHNSON	-4.35%	364B
MERCK & CO., INC.	+17.65%	326B
ABBVIE INC.	+3.77%	286B
ASTRAZENECA PLC	+14.68%	236B
NOVARTIS AG	+4.71%	198B
ROCHE HOLDING AG	-12.43%	194B
PFIZER, INC.	-3.79%	154B